Göran Forsberg will be stepping down with immediate effect and will assist with the transition. During the recruitment process, Board Director, Damian Marron, a veteran four-time CEO, will assume the role of Interim CEO, supported by Chairman, Magnus Persson and the Board.

The Board wishes to recognize and to thank Göran Forsberg for successfully building Cantargia from a concept stage to a company with two promising drug candidates in clinical trials, and for his visionary leadership.

“It has been a pleasure and a privilege to lead Cantargia from a private, research stage company to become the publicly listed, clinical stage company with two highly promising programs that Cantargia is today,” says Göran Forsberg. “I am grateful to all my colleagues without whom this would not have been possible. I look forward to continuing to see Cantargia grow in the months and years to come.”

The Board expresses its gratitude to Damian Marron for lending the company his vast experience in leadership, financing and dealmaking.